Abstract:

Objective　To analyze the expression of miR-6884-5p in non-small cell lung cancer (NSCLC) and its correlations with tumor markers and prognosis. Methods　Samples from 91 NSCLC patients treated in Shangqiu First People's Hospital from January 2017 to January 2019 were collected. Tumor tissues and adjacent non-tumor tissues were collected during surgery. Serum samples from 50 healthy individuals were collected as a control group. NSCLC patients : 55 males and 36 females, aged (60.3±7.4) years ; Control group : 27 males and 23 females, aged (60.1±5.7) years. The relative expression levels of miR-6884-5p in tumor tissues and serum were measured using quantitative real-time PCR (qRT-PCR). The diagnostic value of miR-6884-5p in NSCLC patients was assessed using the receiver operating characteristic curve (ROC). Cox regression analysis was used to identify independent prognostic factors affecting 5-year survival of NSCLC patients. Statistical methods were χ² test and t test. Results　The expression of miR-6884-5p in tumor tissues was lower than that in adjacent non-tumor tissues (P<0.001). The relative expression level of miR-6884-5p in the serum of NSCLC patients was lower than that of the control group (P<0.001). ROC analysis revealed that the area under the curve (AUC) for serum miR-6884-5p in diagnosing NSCLC was 0.863. Serum miR-6884-5p expression was negatively correlated with cancer antigen 125 (CA125) and carcinoembryonic antigen (CEA) levels (both P<0.05). The patients in the miR-6884-5p low expression group had a higher incidence of advanced clinical stages (III+IV) and lymph node metastasis compared to the high expression group (both P<0.01). The 5-year survival rate of the low expression group was lower than that of the high expression group (P<0.05). Multivariate Cox regression analysis showed that miR-6884-5p (HR=0.370, 95%CI 0.206-0.664), age (HR=2.639, 95%CI 1.505-4.627), tumor size (HR=2.415, 95%CI 1.392-4.190), clinical stage (HR=0.339, 95%CI 0.193-0.597), and lymph node metastasis (HR=3.058, 95%CI 1.760-5.311) were independent prognostic factors affecting 5-year survival (all P<0.05). Conclusion　The low expression of miR-6884-5p in NSCLC is closely associated with tumor progression and poor prognosis, suggesting that miR-6884-5p may serve as a potential biomarker and therapeutic target.

Key words:

Non-small cell lung cancer, miR-6884-5p, Tumor markers, Prognosis

摘要：

目的　分析miR-6884-5p在非小细胞肺癌（NSCLC）中的表达，并探讨其与肿瘤标志物的相关性及预后价值。方法　收集2017年1月至2019年1月商丘市第一人民医院治疗的91例NSCLC患者样本。术中采集患者的癌组织及癌旁组织，同时收集50例正常人血清作为对照组。NSCLC患者：男55例，女36例，年龄（60.3±7.4）岁；正常对照组：男27例，女23例，年龄（60.1±5.7）岁。采用实时定量PCR（qRT-PCR）检测NSCLC患者肿瘤组织及血清中miR-6884-5p的相对表达水平。通过受试者操作特征曲线（ROC）分析miR-6884-5p在NSCLC诊断中的价值。采用Cox回归分析影响NSCLC患者5年生存的独立预后因素。统计学方法采用χ²检验和t检验。结果　肿瘤组织中miR-6884-5p的表达低于癌旁组织（P<0.001）；NSCLC患者血清中miR-6884-5p的表达低于正常对照组（P<0.001）。ROC分析显示，血清miR-6884-5p在NSCLC诊断中的曲线下面积为0.863。血清中miR-6884-5p的表达与癌抗原125（CA125）和癌胚抗原（CEA）均呈负相关（均P<0.05）。miR-6884-5p低表达组患者的临床高分期（III+IV）和淋巴结转移数均高于高表达组（均P<0.05），5年生存率低于高表达组（P<0.05）。多因素Cox回归分析发现，miR-6884-5p（HR=0.370，95%CI 0.206～0.664）、年龄（HR=2.639，95%CI 1.505～4.627）、肿瘤大小（HR=2.415，95%CI 1.392～4.190）、临床分期（HR=0.339，95%CI 0.193～0.597）、淋巴结转移（HR=3.058，95%CI 1.760～5.311）是影响患者5年生存的独立预后因素（均P<0.05）。结论　miR-6884-5p在NSCLC中低表达与肿瘤进展及不良预后密切相关，有望成为潜在的生物标志物和治疗靶点。

关键词:

非小细胞肺癌, miR-6884-5p, 肿瘤标志物, 预后